State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Leslie A. Morland, Barbara O Rothbaum, Lauren M. Sippel, Jessica L Maples-Keller, Paula P. Schnurr
Journal of Traumatic Stress March 12, 2026 DOI: 10.1002/jts.70060 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Population | Adults with PTSD |
| Topics | MDMA Psychedelic-assisted therapy PTSD |
| Keywords | Posttraumatic stress Cognition Cognitive behavioral therapy Leverage statistics Cognitive therapy Action physics Intervention counseling Randomized controlled trial Psychotherapist Clinical psychology Scientific literature Medline Clinical trial |
| Citations | 2 |
| Key findings | MDMA-assisted psychotherapy for PTSD has shown promising outcomes in randomized controlled trials but faces significant methodological limitations and has not received FDA approval due to insufficient evidence. |
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promising outcomes in recent randomized controlled trials, with high response and remission rates. However, the U.S. Food and Drug Administration declined to approve MDMA-AT for marketable use in August 2024 due to concerns about insufficient evidence. This paper reviews the current state of the scientific literature on MDMA-AT for PTSD, including putative mechanisms of action; key strengths and limitations of methodologies used to date; gaps in the evidence; and clinical, ethical, and regulatory considerations. Key limitations to be addressed in future studies include challenges with blinding, a lack of active comparator conditions, a lack of head-to-head comparisons of different models, inadequate safety monitoring, and limited sample generalizability. We describe emerging research that integrates MDMA with established trauma-focused therapies, such as prolonged exposure therapy and cognitive processing therapy, to leverage MDMA's effects on known cognitive behavioral mechanisms of action and support future implementation. Future research directions for advancing knowledge and consideration for the dissemination of MDMA-AT are discussed.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
MDMA-assisted psychotherapy has shown promising response and remission rates in randomized trials, but the FDA declined approval in August 2024 citing insufficient evidence, and blinding, active comparators, safety monitoring, and generalizability remain limitations.
Synthesized
Comparable studies
Other narrative reviews on MDMA and psychedelic-assisted therapy, most cited first.